Homocysteine and Methylation: B12, Folate, TMG — Cardiovascular Risk and Protocol

Homocysteine is a sulfur-containing amino acid produced during the metabolism of methionine. It is not obtained directly from diet — it is an intermediate that, under normal conditions, is rapidly recycled back to methionine or converted to cysteine. When recycling is impaired, homocysteine accumulates in blood, and this accumulation is independently associated with cardiovascular disease, stroke, dementia, and all-cause mortality.

Why Homocysteine Matters

Elevated plasma homocysteine (hyperhomocysteinemia) is defined as above 15 micromol/L, with "borderline" elevation starting around 10-12 micromol/L. In large meta-analyses, each 5 micromol/L increase in homocysteine is associated with approximately 20% increased risk of cardiovascular disease and 70% increased risk of venous thromboembolism.

The cognitive implications are significant. A 2018 meta-analysis of prospective studies found that elevated homocysteine was associated with approximately 70% increased risk of dementia and Alzheimer's disease. Mechanistically, homocysteine impairs endothelial function, promotes vascular inflammation, induces DNA strand breaks, and increases tau phosphorylation — the pathological protein modification central to Alzheimer's.

Testing is inexpensive and widely available. A fasting plasma homocysteine level should be part of any comprehensive longevity panel, particularly in adults over 50.

The Methylation Pathway

The recycling of homocysteine depends on the methylation cycle. Two main pathways exist:

Folate and B12-dependent remethylation: 5-methyltetrahydrofolate (5-MTHF, the active form of folate) donates a methyl group to B12 (as methylcobalamin), which then transfers it to homocysteine, converting it back to methionine. This pathway requires adequate dietary folate and B12.

Transsulfuration: Vitamin B6 (as pyridoxal-5-phosphate) is required for converting homocysteine to cystathionine and ultimately to cysteine. This pathway is upregulated when homocysteine levels are high.

TMG (trimethylglycine / betaine): Provides an alternative methyl donor, converting homocysteine to methionine via a B12-independent pathway. This is particularly relevant when B12 or folate levels are adequate but homocysteine remains elevated.

MTHFR Variants

The MTHFR (methylenetetrahydrofolate reductase) gene encodes an enzyme that converts dietary folate to 5-MTHF. Two common variants — C677T and A1298C — reduce enzyme activity by 30-70% depending on genotype. Homozygous C677T (TT genotype) is present in approximately 10-15% of individuals and is associated with significantly elevated homocysteine.

For MTHFR variant carriers, standard folic acid supplementation is less effective — the 5-MTHF (methylfolate) form bypasses the impaired conversion step and directly supports the remethylation pathway. Methylcobalamin (rather than cyanocobalamin) is the preferred B12 form for the same reason.

Genetic testing for MTHFR is not essential before supplementation, but it explains non-response to folic acid in some individuals and guides form selection.

Evidence for B-Vitamin Supplementation

B12, folate, and B6 reliably lower homocysteine. A 2017 Cochrane review of 15 RCTs confirmed that folic acid alone reduced plasma homocysteine by approximately 25%; combined B6 + folic acid lowered it by 32%. B12 supplementation in deficient individuals (B12 below 200 pg/mL) substantially lowers homocysteine — often by 50% or more.

The VITACOG trial in 168 elderly adults with MCI found that B12/folate/B6 supplementation for 2 years significantly slowed brain atrophy (7-fold reduction in atrophy rate) and reduced cognitive decline compared to placebo. Crucially, the benefit was concentrated in the subgroup with elevated baseline homocysteine — again reinforcing that testing first and treating a confirmed deficit is the correct approach.

The HOPE-2 trial and several subsequent trials attempted to demonstrate cardiovascular event reduction with B-vitamin treatment. Results were mixed: homocysteine lowering was consistent, but reduction in cardiovascular events was modest and not statistically significant across all studies. This suggests that elevated homocysteine may be a biomarker of dysregulated methylation and endothelial dysfunction rather than directly causal for events — or that intervention needs to occur earlier in disease progression.

Dosing Protocol

For mild elevation (12-20 micromol/L) with confirmed B12 or folate deficiency:

• Folate as 5-MTHF: 400-800 mcg/day
• Vitamin B12 as methylcobalamin: 500-1000 mcg/day
• Vitamin B6 as P5P: 25-50 mg/day

For persistent elevation despite adequate B12 and folate:

• TMG (trimethylglycine): 500-3000 mg/day in divided doses
• Re-test homocysteine after 8-12 weeks

For MTHFR C677T homozygotes: prioritize methylfolate over folic acid and methylcobalamin over cyanocobalamin.

Testing and Monitoring

• Plasma homocysteine (fasting): baseline, then 8-12 weeks after initiating supplementation
• Serum B12: useful for identifying deficiency, but note that serum B12 has poor sensitivity; functional markers (methylmalonic acid, holotranscobalamin) are more specific
• Red blood cell folate or plasma folate: assess folate status separately from homocysteine
• CBC with differential: macrocytic anemia is a late sign of B12 or folate deficiency; do not wait for anemia to treat

Related pages: Vitamin B12, Folate, Tmg Betaine, Cardiovascular Disease Risk, Age Associated Cognitive Decline, Homocysteine B12 Tmg Methylation Evidence

Evidence Limits and What We Still Need

The evidence that lowering homocysteine prevents cardiovascular events and dementia is weaker than the evidence that elevated homocysteine predicts them — a classic marker-versus-target distinction. The VITACOG trial brain atrophy result has not been replicated in a larger RCT powered for clinical dementia endpoints. Optimal target homocysteine levels are not established by RCT; clinical guidelines vary. MTHFR testing and methylfolate selection add complexity but the clinical benefit of genotype-guided selection versus standard methylfolate supplementation has not been rigorously compared. Most trials have supplemented individuals who may not have had deficiency — confounding interpretation of effect size.

Sources

1. Selhub J, et al. Folate, vitamin B12, and vitamin B6 and one carbon metabolism. J Nutr Health Aging. 2018. https://pubmed.ncbi.nlm.nih.gov/29552813/
2. Smith AD, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG). PLoS One. 2010. https://pubmed.ncbi.nlm.nih.gov/20838622/
3. Clarke R, et al. Lowering blood homocysteine with folic acid based supplements: systematic review. BMJ. 1998. https://pubmed.ncbi.nlm.nih.gov/9552776/
4. Wald DS, et al. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002. https://pubmed.ncbi.nlm.nih.gov/12446535/
5. Balion C, et al. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012. https://pubmed.ncbi.nlm.nih.gov/22936783/
6. Hoogeveen EK, et al. Hyperhomocysteinemia as risk factor for ischemic and hemorrhagic stroke in a large cohort: The Netherlands Cohort Study. Atherosclerosis. 2012. https://pubmed.ncbi.nlm.nih.gov/29083680/